TY - JOUR
T1 - Essential elements of personalized medicine
AU - Burke, Wylie
AU - Brown Trinidad, Susan
AU - Press, Nancy A.
N1 - Funding Information:
This work was supported in part by the National Human Genome Research Institute of the National Institutes of health under award no. P50HG003374 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the institutions with which the authors are affiliated.
PY - 2014/2
Y1 - 2014/2
N2 - Objectives: Genomic information has been promoted as the basis for "personalized" health care. We considered the benefits provided by genomic testing in context of the concept of personalized medicine. Materials and Methods: We evaluated current and potential uses of genomic testing in health care, using prostate cancer as an example, and considered their implications for individualizing or otherwise improving health care. Results and Conclusions: Personalized medicine is most accurately seen as a comprehensive effort to tailor health care to the individual, spanning multiple dimensions. While genomic tests will offer many potential opportunities to improve the delivery of care, including the potential for genomic research to offer opportunities to improve prostate cancer screening and treatment, such advances do not in themselves constitute a paradigm shift in the delivery of health care. Rather, personalized medicine is based on a partnership between clinician and patient that utilizes shared decision making to determine the best health care options among the available choices, weighing the patient's personal values and preferences together with clinical findings. This approach is particularly important for difficult clinical decisions involving uncertainty and trade-offs, such as those involved in prostate cancer screening and management. The delivery of personalized medicine also requires adequate health care access and assurance that basic health needs have been met. Substantial research investment will be needed to identify how genomic tests can contribute to this effort.
AB - Objectives: Genomic information has been promoted as the basis for "personalized" health care. We considered the benefits provided by genomic testing in context of the concept of personalized medicine. Materials and Methods: We evaluated current and potential uses of genomic testing in health care, using prostate cancer as an example, and considered their implications for individualizing or otherwise improving health care. Results and Conclusions: Personalized medicine is most accurately seen as a comprehensive effort to tailor health care to the individual, spanning multiple dimensions. While genomic tests will offer many potential opportunities to improve the delivery of care, including the potential for genomic research to offer opportunities to improve prostate cancer screening and treatment, such advances do not in themselves constitute a paradigm shift in the delivery of health care. Rather, personalized medicine is based on a partnership between clinician and patient that utilizes shared decision making to determine the best health care options among the available choices, weighing the patient's personal values and preferences together with clinical findings. This approach is particularly important for difficult clinical decisions involving uncertainty and trade-offs, such as those involved in prostate cancer screening and management. The delivery of personalized medicine also requires adequate health care access and assurance that basic health needs have been met. Substantial research investment will be needed to identify how genomic tests can contribute to this effort.
KW - Genetics
KW - Genomics
KW - Health technology assessment
KW - Personalized medicine
KW - Pharmacogenomics
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84892547340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892547340&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2013.09.002
DO - 10.1016/j.urolonc.2013.09.002
M3 - Article
C2 - 24321254
AN - SCOPUS:84892547340
SN - 1078-1439
VL - 32
SP - 193
EP - 197
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 2
ER -